Clinical Advances in Hematology & OncologyCases in the Management of Nonmetastatic Castration-Resistant Prostate Cancer: Darolutamide Added to Leuprolide in a 73-Year-Old Patient

In this case, the second in a three-part series, a man was diagnosed with prostate cancer based on a prostate-specific antigen (PSA) level of 6.5 ng/mL. The initial diagnosis was stage 3 disease (T3, N0, M0), with a Gleason score of 3+4=7. The rationale for the treatment decisions is explained, along with the trials (ARAMIS, SPARTAN, PROSPER) that influenced the decisions.